Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: LCP1

Summary for LCP1

Gene information	Gene symbol	LCP1
	Ensembl ID	ENSG00000136167
	Entrez ID	3936
	Gene name	lymphocyte cytosolic protein 1
	Synonyms	CP64\|L-PLASTIN\|LC64P\|PLS2
	Gene type	protein_coding
	UniProtAcc	P13796

Top

Dataset with differentially expressed gene: LCP1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.319662	5.16e-05
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	0.696783	1.14e-06
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.37007	4.13e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.604903	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.364597	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.376683	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.362218	2.40e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.295848	6.87e-17
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.398757	4.69e-36
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.939155	3.55e-34
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.567007	4.76e-09
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.484221	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.406296	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.407387	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.266481	9.40e-25
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.442016	3.21e-08
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.726343	2.68e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.271397	5.03e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.265842	2.74e-21
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.945775	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.259586	8.01e-04
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	0.56976	8.48e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.438401	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.320349	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.37464	5.33e-42
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.470421	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.857981	4.79e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.353649	4.05e-05
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.291382	1.11e-08
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.314634	6.47e-14
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.335191	1.63e-12
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.34844	0.00e+00

Top

Expression of LCP1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to LCP1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating LCP1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
LCP1	hsa-miR-624-5p	95.497	NM_002298
LCP1	hsa-miR-885-5p	92.6156	NM_002298
LCP1	hsa-miR-3978	91.4655	NM_002298
LCP1	hsa-miR-5586-5p	91.1908	NM_002298
LCP1	hsa-miR-647	90.1848	NM_002298
LCP1	hsa-miR-6822-5p	89.2278	NM_002298
LCP1	hsa-miR-6750-5p	89.2278	NM_002298
LCP1	hsa-miR-518f-5p	87.6683	NM_002298
LCP1	hsa-miR-518d-5p	87.6683	NM_002298
LCP1	hsa-miR-520c-5p	87.6683	NM_002298
LCP1	hsa-miR-526a-5p	87.6683	NM_002298
LCP1	hsa-miR-218-1-3p	85.7856	NM_002298
LCP1	hsa-miR-12133	84.7156	NM_002298
LCP1	hsa-miR-96-5p	84.7156	NM_002298
LCP1	hsa-miR-1271-5p	84.7156	NM_002298
LCP1	hsa-miR-3714	83.5635	NM_002298
LCP1	hsa-miR-506-3p	83.301	NM_002298
LCP1	hsa-miR-124-3p	83.301	NM_002298
LCP1	hsa-miR-6836-3p	82.8335	NM_002298
LCP1	hsa-miR-3910	82.0389	NM_002298
LCP1	hsa-miR-6867-5p	81.94	NM_002298
LCP1	hsa-miR-523-5p	81.4185	NM_002298
LCP1	hsa-miR-522-5p	81.4185	NM_002298
LCP1	hsa-miR-518e-5p	81.4185	NM_002298
LCP1	hsa-miR-519c-5p	81.4185	NM_002298
LCP1	hsa-miR-519a-5p	81.4185	NM_002298
LCP1	hsa-miR-519b-5p	81.4185	NM_002298
LCP1	hsa-miR-34b-5p	81.0675	NM_002298
LCP1	hsa-miR-449c-5p	81.0675	NM_002298
LCP1	hsa-miR-2682-5p	81.0675	NM_002298
LCP1	hsa-miR-5696	80.8302	NM_002298
LCP1	hsa-miR-3059-5p	80.0171	NM_002298

Page: 1

Top

Motifs and transcription factors (TFs) regulating LCP1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
LCP1	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
LCP1	transfac_pro__M00655	ETV4 (directAnnotation).
LCP1	swissregulon__hs__SPI1	SPI1 (directAnnotation).
LCP1	metacluster_167.7	IRF8 (inferredBy_Orthology).
LCP1	transfac_pro__M02269	FEV (directAnnotation).
LCP1	homer__ACAGGATGTGGT_ETS_RUNX	RUNX1 (directAnnotation).
LCP1	tfdimers__MD00066	ELF1 (directAnnotation).
LCP1	transfac_pro__M04870	HDAC2 (directAnnotation).
LCP1	taipale_tf_pairs__ETV2_DLX3_RSCGGAANNNNNNNTAATKR_CAP_repr	DLX3; ETV2 (directAnnotation).
LCP1	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).
LCP1	taipale_tf_pairs__HOXB2_ELF1_NNYMATTANNNNNNNGGAAGNN_CAP_repr	ELF1; HOXB2 (directAnnotation).
LCP1	taipale_tf_pairs__ERF_HOXA3_RSCGGAWNNNNNNNYMATTA_CAP_repr	ERF; HOXA3 (directAnnotation).
LCP1	hdpi__FLI1	FLI1 (directAnnotation).
LCP1	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
LCP1	taipale__ELK1_full_NACTTCCGSCGGAARMN_repr	ELK1 (directAnnotation).
LCP1	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	ETV4; FOXO1 (directAnnotation).
LCP1	taipale_tf_pairs__FLI1_FOXI1_RCCGGATGTTKWY_CAP	FLI1; FOXI1 (directAnnotation).
LCP1	taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP	ETV5; EVX1 (directAnnotation).
LCP1	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGNNNNNNYMATTA_CAP	ETV2; HOXA2 (directAnnotation).
LCP1	transfac_pro__M06102	ZNF16 (directAnnotation).
LCP1	metacluster_144.10	ZNF100 (directAnnotation).
LCP1	transfac_pro__M06506	ZFP62 (directAnnotation).
LCP1	metacluster_141.2	E2F2; E2F3 (directAnnotation).
LCP1	taipale_tf_pairs__ETV5_FOXI1_TGTTGNCGGAWRN_CAP	ETV5; FOXI1 (directAnnotation).
LCP1	jaspar__MA1708.1	ETV7 (directAnnotation).
LCP1	transfac_pro__M06173	ZNF85 (directAnnotation).
LCP1	metacluster_141.6	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).
LCP1	transfac_pro__M06259	ZNF91 (directAnnotation).
LCP1	transfac_pro__M06700	ZNF71 (directAnnotation).
LCP1	transfac_pro__M04826	EP300 (directAnnotation).
LCP1	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	ELK1; TEF (directAnnotation).
LCP1	transfac_pro__M06678	ZNF287 (inferredBy_Orthology).
LCP1	jaspar__MA0136.3	ELF5 (inferredBy_Orthology).
LCP1	transfac_pro__M06589	ZNF778 (directAnnotation).
LCP1	transfac_pro__M05317	SOX30 (directAnnotation).
LCP1	transfac_pro__M05744	ZXDC (directAnnotation).
LCP1	taipale_tf_pairs__TEAD4_SPIB_RGAATGCGGAAGTN_CAP_1	SPIB; TEAD4 (directAnnotation).
LCP1	tfdimers__MD00475	FOS; FOSB; FOSL1; FOSL2; JUN; JUNB; JUND; ZNF333 (directAnnotation).
LCP1	taipale_tf_pairs__TEAD4_SPIB_RGAATGCGGAAGTN_CAP_2	SPIB; TEAD4 (directAnnotation).
LCP1	transfac_pro__M06251	ZSCAN2 (inferredBy_Orthology).
LCP1	kznf__ZNF805_Imbeault2017_RP_RCADE	ZNF805 (directAnnotation).
LCP1	dbtfbs__ZNF610_HEK293_ENCSR691TXI_merged_N1	ZNF610 (directAnnotation).
LCP1	transfac_pro__M06692	PRDM10 (directAnnotation).
LCP1	taipale_tf_pairs__TEAD4_FOXI1_RCATWCCNNNNNNNNNNNNNNRTMAACA_CAP_repr	FOXI1; TEAD4 (directAnnotation).
LCP1	swissregulon__mm__Nr3c1	NR3C1 (inferredBy_Orthology).
LCP1	transfac_pro__M06463	ZNF595 (directAnnotation).
LCP1	taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr	CEBPD; ETV2 (directAnnotation).
LCP1	tfdimers__MD00129	CRX; NKX3-2 (directAnnotation).
LCP1	transfac_pro__M06557	ZNF418 (directAnnotation).
LCP1	metacluster_69.2	DMRT1; DMRT1 (directAnnotation). DMRTB1; DMRTB1 (inferredBy_Orthology).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."